IMVT(IMVT)
IMVT
ANALYST COVERAGE23 analysts
BUY
▲ +73.1%upside to target
L $41.00
Med $45.50consensus
H $50.00PRICE
Prev Close
26.53
Open
26.25
Day Range25.75 – 26.35
25.75
26.35
52W Range13.79 – 30.16
13.79
30.16
76% of range
VOLUME & SIZE
Avg Volume
1.4M
FUNDAMENTALS
P/E Ratio
-9.8x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.37
Market-like
TECHNICAL
RSI (14)
62
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 20
DEx-Dividend
In 90 days
Aug 17
PDividend Pay
In 97 days
Aug 24
Key MetricsTTM
Market Cap$5.35B
Revenue TTM$0.00
Net Income TTM-$464.20M
Free Cash Flow-$423.09M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-65.8%
Return on Assets-44.1%
Debt / Equity0.00
Current Ratio15.74
EPS TTM$-2.56
IMVT News
About
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Sector
Industry
Biological Product (except Diagnostic) Manufacturing
Website
Frank TortiExecutive Chairperson of the Board
Jay S. StoutChief Technology Officer
William L. MaciasCMO Emeritus
Eric VenkerChief Executive Officer & Director
Julie KirschlingSenior Vice President of Program & Alliance Management
Melanie GloriaChief Operating Officer
Sheetal PatelSenior Vice President of Clinical Development
Yan ZhengSenior Vice President of Biostatistics, Programming & Data Management
Andy DeigSenior Vice President of Strategic Finance
Christopher Van TuylChief Legal Officer & Corporate Secretary
Tiago GiraoChief Financial Officer
Becky MerlinaSenior VP & Global Head of Quality
Christine BlodgettSenior Vice President of Human Resources